Nivolumab: observed
229 studies: patients on it are followed, or it is given outside a trial. Page 1 of 3. Open to participants first (50), then studies with results posted, then the rest; newest registration first within each.
- Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGCNot yet recruitingNCT07899775Report a problem
- Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaRecruitingNCT07856212Report a problem
- Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingNCT07786792Report a problem
- Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLCNot yet recruitingNCT07752589Report a problem
- First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)RecruitingNCT07679061Report a problem
- ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)Not yet recruitingNCT07661251Report a problem
- Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerRecruitingNCT07419932Report a problem
- Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)RecruitingNCT07394062Report a problem
- Large Granular Lymphocytes in mNSCLC Treated With NivolumabRecruitingNCT07363811Report a problem
- Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaRecruitingNCT07223411Report a problem
- First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)RecruitingNCT07190677Report a problem
- A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)RecruitingNCT07169708Report a problem
- Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentRecruitingNCT07147101Report a problem
- Impact of CES1 Genotype on Capecitabine Exposure in Cancer PatientsRecruitingNCT07114627Report a problem
- TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune MicroenvironmentRecruitingNCT07100405Report a problem
- MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.RecruitingNCT07092670Report a problem
- Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenRecruitingNCT07061379Report a problem
- Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07054086Report a problem
- Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung CancerNot yet recruitingNCT07035860Report a problem
- GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment (BTC-IM-1)RecruitingNCT06988592Report a problem
- Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerRecruitingNCT06926179Report a problem
- Observational Study of Patients with Advanced Melanoma (skin Cancer) to Assess If IOpener®-melanoma Test Can Predict Response to Immunotherapy.RecruitingNCT06784778Report a problem
- Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life ContextRecruitingNCT06781450Report a problem
- Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.RecruitingNCT06724159Report a problem
- The Effect of Serum Ferritin in irAERecruitingNCT06702566Not applicableReport a problem
- The Immune Assessment of PD-1 Antibody Therapy in TumorRecruitingNCT06693440Report a problem
- Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant AppRecruitingNCT06675643Report a problem
- Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma ManagementRecruitingNCT06627595Report a problem
- Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic NeviRecruitingNCT06599619Report a problem
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingNCT06532149Report a problem
- Gastric Cancer Organoids in the Screening of Neoadjuvant DrugsRecruitingNCT06196554Report a problem
- DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT06194695Report a problem
- An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyRecruitingNCT06169956Report a problem
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT05717738Report a problem
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994Report a problem
- Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung CancerRecruitingNCT05655663Not applicableReport a problem
- Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint InhibitorsRecruitingNCT05649683Not applicableReport a problem
- Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282Report a problem
- Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected MelanomaRecruitingNCT05527795Report a problem
- Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLCRecruitingNCT05418660Report a problem
- International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
- Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT05260606Report a problem
- Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingNCT05139706Report a problem
- Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational StudyRecruitingNCT04680598Report a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNCT04659343Report a problem
- Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin ToxicityRecruitingNCT04631731Phase 1/2Report a problem
- Immunotherapy in Lung Cancer: Treatment After IO Cessation.RecruitingNCT04465942Report a problem
- JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingNCT04294771Report a problem
- Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationNCT04291755Report a problem
- Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingNCT04107168Report a problem
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results postedReport a problem
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedNCT05363072Results postedReport a problem
- Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)CompletedNCT03963518Results postedReport a problem
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results postedReport a problem
- First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingNCT07852884Report a problem
- Pharmacokinetic Study of Therapeutic Plasma ExchangeWithdrawnNCT07756242Report a problem
- Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaActive, not recruitingNCT07718139Report a problem
- Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeActive, not recruitingNCT07663786Report a problem
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruitingNCT07645209Report a problem
- Treatment Patterns and Characteristics of Patients Prescribed Opdivo QvantigCompletedNCT07636863Report a problem
- Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in PolandCompletedNCT07526961Report a problem
- Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records DatabasesActive, not recruitingNCT07485166Report a problem
- Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant MelanomaActive, not recruitingNCT07428252Not applicableReport a problem
- Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center AnalysisCompletedNCT07256184Report a problem
- Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%CompletedNCT07215962Report a problem
- Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI StudyCompletedNCT07192926Report a problem
- A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLCCompletedNCT07141563Report a problem
- Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal FailureTerminatedNCT07117409Report a problem
- Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung CarcinomaCompletedNCT07111104Report a problem
- A Benefit Population Atlas of nICT Versus nCT for LAGCCompletedNCT07098104Report a problem
- Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabCompletedNCT07091695Report a problem
- Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron DatabaseCompletedNCT07079644Report a problem
- Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1CompletedNCT07036016Report a problem
- Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyCompletedNCT07024862Report a problem
- Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaCompletedNCT06771674Report a problem
- Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in FranceCompletedNCT06735781Report a problem
- A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint InhibitorsActive, not recruitingNCT06630429Report a problem
- Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCCCompletedNCT06607809Report a problem
- An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaNo longer availableNCT06590480Report a problem
- Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceActive, not recruitingNCT06504615Report a problem
- Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction CancerCompletedNCT06499298Report a problem
- A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06487156Report a problem
- A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction CancerCompletedNCT06452329Report a problem
- Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT06440811Report a problem
- Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in FranceTerminatedNCT06421311Report a problem
- Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in CanadaCompletedNCT06361576Report a problem
- Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in CanadaCompletedNCT06361563Report a problem
- Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsCompletedNCT06345183Report a problem
- Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)WithdrawnNCT06283238Report a problem
- Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138Report a problem
- The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric CancerActive, not recruitingNCT06235164Report a problem
- Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and ChemotherapyCompletedNCT06202781Report a problem
- A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With MelanomaCompletedNCT06163170Report a problem
- CX3CR1+T Cell Predict Immunotherapy EfficacyCompletedNCT06054152Report a problem
- Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRCCompletedNCT06031376Report a problem
- Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal CancerCompletedNCT06011330Report a problem
- Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal CancerCompletedNCT05942768Report a problem
- EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem
- Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2Report a problem
- A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal CancerTerminatedNCT05780736Report a problem